Status:
COMPLETED
The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
Lead Sponsor:
University of Alabama at Birmingham
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Multiple Myeloma (MM) patients are prone to poor quality of life (QoL) as a result of the anxiety and depression they suffer due to a poor understanding of their disease. Improving patient understandi...
Detailed Description
The purpose of this research study is to see if the MPI educational program, implemented in parallel with standard of care treatment, can improve overall quality of life (QoL) for MM patients. This pr...
Eligibility Criteria
Inclusion
- Of age ≥18 years or older.
- Having a diagnosis of MM; newly diagnosed or relapsed/refractory disease
- Undergoing systemic treatment through the UAB MM Clinic Pathway
- Able to provide informed consent to be included in the intervention
- MM patients in a prior/concurrent (non-pyscho/educational intervention), MM study will be eligible to participate
- Have either SMS texting or email access to receive encouragement messages
Exclusion
- Patients will be ineligible for the program if they are:
- Being treated by end-of-life or comfort care measures only
- MM patients not treated through the UAB MM Clinic Pathway.
- MM patients not requiring systemic therapy.
- Patients with a diagnosis of MGUS or SMM.
- Have a history of other malignancy within the past \[3 or 5\] years with the exception of:
- Malignancies treated with curative intent and with no known active disease present for ≥ 3 (or 5) years before enrollment and felt to be at low risk for recurrence by the treating physician
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
- Adequately treated breast ductal carcinoma in situ without evidence of disease
- Prostatic intraepithelial neoplasia without evidence of prostate cancer
- Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ
- Are enrolled in a prior/concurrent MM psycho-educational study
- Other Exclusions:
- Patients who do not have either SMS texting or email access to receive encouragement messaging will be excluded
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
Key Trial Info
Start Date :
November 27 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 22 2024
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT03777306
Start Date
November 27 2017
End Date
November 22 2024
Last Update
November 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233